Brain scan breakthrough? new tracer targets protein tangles in MSA and Parkinson's
NCT ID NCT06032026
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new radioactive tracer called 11C-HY-2-15, designed to detect abnormal alpha-synuclein protein in the brain. Researchers will scan 70 adults with multiple system atrophy, Parkinson's disease, progressive supranuclear palsy, or healthy volunteers to see if the tracer can distinguish these conditions. The goal is to improve diagnosis of these brain protein disorders.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
11C-HY-2-15 (a radioactive tracer for PET scans)
What this could lead to
If successful, this could lead to a new way to diagnose and distinguish diseases like multiple system atrophy, Parkinson's, and progressive supranuclear palsy using brain scans.
What could go wrong
This is an early Phase I study with only 70 participants, so the tracer may not reliably detect the intended protein or may have safety issues. Results may not apply to broader populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact